osteoclast activating factor

06/01/1996 - "This usually results from an imbalance between the osteoclast and osteoblast activity of bone resorption and formation due to the secretion of an osteoclast-activating factor by the myeloma cells. "
08/13/1982 - "[Osteoclast activating factor - a new humoral agent influencing pathological bone resorption]."
07/01/1977 - "We have further characterized osteoclast activating factor (OAF) using a bioassay for bone resorption which utilizes the release of previously incorporated (45)Ca from fetal rat long bones in organ culture. "
05/01/1981 - "Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor."
03/01/1990 - "A number of cytokines have been found to be potent regulators of bone resorption and to share the properties originally attributed to osteoclast-activating factor. "

07/01/1990 - "Primary bone marrow lymphomata are infrequent; most of them are of B-cell origin, and those of a T-cell lineage produce mainly both hypercalcemia and osteolytic lesions apparently due to abnormal production of osteoclast-activating factor. "
03/15/1987 - "Our findings are consistent with the mechanism proposed by several investigators, that the malignant T-lymphocytes produced an osteoclast-activating-factor-like substance that caused osteoclast proliferation and hypercalcemia."
01/01/1983 - "The pathogenesis of hypercalcemia is discussed: the eventuality of a tumoral osteoclast activating factor is suggested."
02/01/1981 - "These findings suggest that hypercalcemia resulted from in-vitro osteoclast activation by tumor cell product(s), one of which may be similar, if not identical, to the lymphocyte product osteoclast-activating factor. "
05/18/1979 - "The reported case is one of lymphoblastic acute leukemia and hypercalcemia associated with osteoclast activating factor secreted by leukemic cells. "

02/01/1997 - "This case suggests either the presence of an unknown systemic osteoclast-activating factor from an occult tumor or a primary malignant hyperosteoclastosis."
05/01/1987 - "The production by the tumor cells of an osteoblast-activating factor, besides the osteoclast-activating factor described earlier by others, is postulated."
07/01/1982 - "Tumor cells from two patients in short-term culture secreted osteoclast-activating factor(s). "
02/01/1981 - "These findings suggest that hypercalcemia resulted from in-vitro osteoclast activation by tumor cell product(s), one of which may be similar, if not identical, to the lymphocyte product osteoclast-activating factor. "
02/01/1985 - "Prostaglandin-dependent and osteoclast-activating factor-mediated hypercalcemic states associated with neoplasia have suppressed serum PTH levels. "

05/01/1984 - "Multiple myeloma is almost always osteolytic, with very little new bone formation and extensive osteoclast activity related to osteoclast activating factor, whereas skeletal uptake of 99Tcm-diphosphonate seems to be related mainly to osteoblastic process. "
01/01/1981 - "Measurements of total body myeloma cell number and osteoclast activating factor (OAF) production by bone marrow myeloma cells in vitro were made in 33 patients with plasma cell myeloma. "
05/01/1981 - "Observations on the mechanism of bone resorption induced by multiple myeloma marrow culture fluids and partially purified osteoclast-activating factor."
01/01/1981 - "Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma."
01/01/2016 - "Receptor activator of nuclear factor-kappa B ligand (RANKL) appears to be an osteoclast-activating factor, bearing an important role in the pathogenesis of multiple myeloma. "

05/01/1992 - "Interleukin-1 (also known as osteoclast activating factor, OAF) is a cytokine produced primarily by monocytes and macrophages and is thought to mediate many of the immunologic, metabolic, and endocrine alterations seen with microbial infection, tissue injury, inflammatory disease, and bone loss. "
05/01/1992 - "Interleukin-1 (also known as osteoclast activating factor, OAF) is a cytokine produced primarily by monocytes and macrophages and is thought to mediate many of the immunologic, metabolic, and endocrine alterations seen with microbial infection, tissue injury, inflammatory disease, and bone loss. "